» Articles » PMID: 27178817

MiR-1908 Overexpression Inhibits Proliferation, Changing Akt Activity and P53 Expression in Hypoxic NSCLC Cells

Overview
Journal Oncol Res
Specialty Oncology
Date 2016 May 15
PMID 27178817
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

The ribosomal protein (RP)-p53 pathway has been shown to play a key role in apoptosis and senescence of cancer cells. miR-1908 is a newly found miRNA that was reported to have prognostic potential in melanoma. However, its role and mechanism in the progression of non-small cell lung cancer (NSCLC) are largely unknown. In this study, we found that expression of miR-1908 was significantly downregulated in human NSCLC cell lines, including SK-MES-1, A549, and NCI-H460. Then the role of miR-1908 in NSCLC cell proliferation was explored. The miR-1908 mimic was transfected into NSCLC cell lines, and their proliferation was detected. MTT and Cell Titer-Blue H analyses showed that the cell proliferation was notably reduced by the miR-1908 mimic transfection. Moreover, we found the RP-p53 pathway was activated by miR-1908 mimic. Moreover, the miR-1908 inhibitor transfection had a completely opposite effect on the NSCLC cell proliferation than that of miR-1908 mimic. To explore the underlying mechanism of that, TargetScan bioinformatics server and 3'-UTR luciferase reporter assay were applied to identify the targets of miR-1908. Our results showed that AKT1 substrate 1 (AKT1S1), a newly proven suppressor of the RP-p53 pathway, was a target of miR-1908, suggesting a probable mechanism for miR-191 suppressing NSCLC cell proliferation. Our findings provide a novel molecular target for the regulation of NSCLC cell proliferation.

Citing Articles

Regulation of Cancer-Associated miRNAs Expression under Hypoxic Conditions.

Valencia-Cervantes J, Sierra-Vargas M Anal Cell Pathol (Amst). 2024; 2024:5523283.

PMID: 38766303 PMC: 11101257. DOI: 10.1155/2024/5523283.


Modulation of AKT Pathway-Targeting miRNAs for Cancer Cell Treatment with Natural Products.

Shiau J, Chuang Y, Yen C, Chang F, Yang K, Hou M Int J Mol Sci. 2023; 24(4).

PMID: 36835100 PMC: 9961959. DOI: 10.3390/ijms24043688.


miR-1908: a microRNA with diverse functions in cancers and non-malignant conditions.

Ghafouri-Fard S, Khoshbakht T, Hussen B, Taheri M, Samsami M Cancer Cell Int. 2022; 22(1):281.

PMID: 36100870 PMC: 9469614. DOI: 10.1186/s12935-022-02709-5.


miR-1908 Dysregulation in Human Cancers.

Shen J, Wu Y, Ruan W, Zhu F, Duan S Front Oncol. 2022; 12:857743.

PMID: 35463352 PMC: 9021824. DOI: 10.3389/fonc.2022.857743.


The miR-1908/SRM regulatory axis contributes to extracellular vesicle secretion in prostate cancer.

Urabe F, Kosaka N, Sawa Y, Ito K, Kimura T, Egawa S Cancer Sci. 2020; 111(9):3258-3267.

PMID: 32558033 PMC: 7469824. DOI: 10.1111/cas.14535.


References
1.
Lawlor M, Alessi D . PKB/Akt: a key mediator of cell proliferation, survival and insulin responses?. J Cell Sci. 2001; 114(Pt 16):2903-10. DOI: 10.1242/jcs.114.16.2903. View

2.
Qin Q, Furong W, Baosheng L . Multiple functions of hypoxia-regulated miR-210 in cancer. J Exp Clin Cancer Res. 2014; 33:50. PMC: 4060094. DOI: 10.1186/1756-9966-33-50. View

3.
Das F, Dey N, Venkatesan B, Kasinath B, Ghosh-Choudhury N, Ghosh Choudhury G . High glucose upregulation of early-onset Parkinson's disease protein DJ-1 integrates the PRAS40/TORC1 axis to mesangial cell hypertrophy. Cell Signal. 2011; 23(8):1311-9. PMC: 3104472. DOI: 10.1016/j.cellsig.2011.03.012. View

4.
Pencheva N, Tavazoie S . Control of metastatic progression by microRNA regulatory networks. Nat Cell Biol. 2013; 15(6):546-54. PMC: 4678324. DOI: 10.1038/ncb2769. View

5.
Long C, Jiang L, Wei F, Ma C, Zhou H, Yang S . Integrated miRNA-mRNA analysis revealing the potential roles of miRNAs in chordomas. PLoS One. 2013; 8(6):e66676. PMC: 3691184. DOI: 10.1371/journal.pone.0066676. View